Physician profile
Michael G Mackey
NPI 1437127800
$1,184.84
in general payments reported to CMS, 2019-2025
22 companies · $54.67 in 2025
The $54.67 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $120 · 2022: $178 · 2023: $594 · 2024: $114 · 2025: $54.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $677 · Education: $85.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.82 |
| Education | $85.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $343.11 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $146.96 | 2020-2023 | Rexulti |
| Abbott Laboratories | $123.50 | 2019 | |
| Cordis US Corp. | $58.59 | 2023 | Brite Tip Radianz |
| Amgen INC. | $56.48 | 2023 | Evenity, Prolia, Tavneos |
| Astrazeneca Pharmaceuticals LP | $55.88 | 2020-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.51 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.73 | 2024-2025 | Jardiance |
| Travere Therapeutics, INC. | $35.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $34.42 | 2022 | |
| Novo Nordisk INC | $32.27 | 2023 | Ozempic |
| Idorsia Pharmaceuticals US INC | $27.16 | 2023 | Quviviq |
| Abbvie INC. | $24.68 | 2023 | |
| Edwards Lifesciences Corporation | $23.87 | 2024 | Sapien 3 Ultra Resilia |
| Cvrx, INC. | $23.47 | 2025 | Barostim Neo System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $22.11 | 2023 | Lupkynis |
| Axsome Therapeutics, INC. | $19.38 | 2023 | Auvelity |
| Lundbeck LLC | $16.22 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $15.17 | 2025 | Capvaxive, Gardasil 9 |
| Calliditas Therapeutics US INC. | $13.79 | 2022 | |
| Dexcom, INC. | $13.24 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mackey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.